Arrowhead's ARO-MUC5AC trial marked terminated for business reasons; results posted to registry
A Phase 1/2a study of inhaled ARO-MUC5AC in healthy volunteers, asthma, and COPD patients was stopped early and has now shown results in the trial registry.
This week's registry update centers on a single terminated Arrowhead Pharmaceuticals study.
- The Phase 1/2a study evaluated the safety, tolerability, and pharmacokinetics of ARO-MUC5AC in normal healthy volunteers and patients with moderate-to-severe asthma and moderate-to-severe chronic obstructive pulmonary disease.1 The trial's overall status is listed as terminated, with the reason given as a sponsor business decision1, and enrollment reached 78 participants.1 Results were first posted to the registry on 2026-09-14.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.